BioCorRx получила национальные коды для препарата LUCEMYRA

EQS-News: BioCorRx Inc: BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply EQS-News: BioCorRx Inc / Key word(s): Financial BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply 25.08.2026 / 14:20 CET/CEST The issuer is solely responsible for the content of this announcement. Updated NDC Records Advance BioCorRx's Commercial Transition Across all Four Product Configurations While Supporting Continuity of Product Availability ANAHEIM, CA - August 25, 2026 (NEWMEDIAWIRE) - BioCorRx Inc (OTC: BICX) (the "Company"), a developer and provider of innovative treatment support programs for substance abuse and related disorders, today announced that its subsidiary, BioCorRx Pharmaceuticals Inc, has successfully established its new, dedicated National Drug Code (NDC) numbers for both LUCEMYRA (lofexidine) 0.18 mg tablets and its accompanying Authorized Generic (AG) presentation. LUCEMYRA is an FDA-approved, non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The establishment of BioCorRx Pharmaceuticals' dedicated NDCs represents the final structural milestone in the transition of the LUCEMYRA asset following its commercial acquisition from USWM, LLC. To maintain an uninterrupted supply chain flow across national wholesale networks, specialized distributors, and retail pharmacy counters, electronic health records (EHR) and institutional pharmacy master files should update order files immediately. The new NDCs seamlessly transition the commercial portfolio over to BioCorRx's registered baseline identifier sequences (Labeler Code: 85789) across all four distinct SKUs: Product Presentation Packaging Configuration Existing NDC New BioCorRx NDC LUCEMYRA 36-count Bottle 78670-050-36 85789-801-36 LUCEMYRA 96-count Bottle 78670-050-96 85789-801-96 Lofexidine HCI (AG) 36-count Bottle 66993-021-36 85789-901-36 Lofexidine HCI (AG) 96-count Bottle 66993-021-96 85789-901-96 "Ensuring that patients navigating opioid withdrawal experience as little disruption as possible at the pharmacy counter remains a top operational priority for us," said Lourdes Felix, Chief Executive Officer of BioCorRx Inc "We are coordinating directly with key healthcare distributors to establish our new NDCs across national drug databases for both LUCEMYRA and its Authorized Generic. This work is intended to support a seamless transition to the BioCorRx NDCs while maintaining continuity of product availability throughout the distribution and pharmacy channels." Distribution and Availability Update System Integration: BioCorRx is coordinating the transition of the newly established NDC numbers for all four product configurations across pharmaceutical databases and downstream distribution systems to support the upcoming commercial rollout. Commercial Availability: BioCorRx expects commercial shipments of the newly coded Brand and Authorized Generic bottles to begin rolling out to regional distribution hubs over the coming weeks. Inventory Continuity: Existing product under the historical NDCs will continue to support market demand during the transition to the new BioCorRx NDCs, helping maintain continuity of product availability throughout the distribution and pharmacy channels. About BioCorRx Inc BioCorRx Inc. (OTC: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx. BioCorRx also operates through its subsidiary, BioCorRx Pharmaceuticals Inc, which focuses on pharmaceutical commercialization and development, including LUCEMYRA (lofexidine) - an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults - and the development of BICX104, an investigational implantable naltrexone pellet program. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com. About LUCEMYRA (lofexidine) LUCEMYRA (lofexidine), an oral tablet, is a central alpha 2-adrenergic agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal. It is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. In clinical trials, LUCEMYRA reduced the severity of withdrawal symptoms compared to placebo, as reported by patients experiencing opioid withdrawal. LUCEMYRA is administered orally for up to 14 days, with dosing guided by symptoms. LUCEMYRA should be discontinued with gradual dose reduction over two to four days. The most common adverse reactions are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. Important Safety Information What is LUCEMYRA? LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when you stop taking an opioid suddenly. LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for opioid use disorder. LUCEMYRA can cause serious side effects, including low blood pressure, slow heart rate, and fainting. Watch for symptoms of low blood pressure or heart rate, including dizziness, lightheadedness, or feeling faint at rest or when quickly standing up; if you experience these symptoms, call your healthcare provider right away and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider. Avoid becoming dehydrated or overheated and be careful not to stand up too suddenly from lying or sitting, as these may increase your risk of low blood pressure and fainting. When your treatment is complete, you will need to stop taking LUCEMYRA gradually, or your blood pressure could increase. After a period of not using opioid drugs, you can become more sensitive to the effects of opioids if you start using them again. This may increase your risk of overdose and death. Before taking LUCEMYRA, tell your healthcare provider about all your medical conditions, including if you have low blood pressure, slow heart rate, any heart problems including history of heart attack or a condition called long QT syndrome, liver or kidney problems, or if you drink alcohol. Tell your healthcare provider if you are pregnant, plan on becoming pregnant, or are breastfeeding; it is not known if LUCEMYRA can harm your unborn baby or whether LUCEMYRA passes into your breast milk. Especially tell your healthcare provider if you take benzodiazepines, barbiturates, tranquilizers, or sleeping pills, as taking these with LUCEMYRA can cause serious side effects. The most common side effects of LUCEMYRA include low blood pressure or symptoms of low blood pressure such as lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact BioCorRx Pharmaceuticals Inc at 1-833-LUCEMYRA. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Click here to see full Prescribing Information. About BICX104 BICX104 is BioCorRx's investigational biodegradable naltrexone implant technology designed to provide controlled delivery of naltrexone. A prior clinical study evaluating the Company's implant technology was completed in 2023 (ClinicalTrials.gov Identifier: NCT04828694). A new clinical study evaluating BICX104 commenced in January 2026 (ClinicalTrials.gov Identifier: NCT07269873), with additional studies planned. The current clinical study is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Prior research evaluating the Company's implant technology was also supported in part by the National Institute on Drug Abuse. About Naltrexone Naltrexone is an opioid receptor antagonist that blocks the effects of opioids at the mu-opioid receptor. It has been approved by the U.S. Food and Drug Administration (FDA) in oral and extended-release injectable forms for the treatment of opioid use disorder and alcohol dependence. By blocking opioid receptors, naltrexone can prevent the euphoric and sedative effects of opioids. Naltrexone has also been studied for potential use in other conditions, including substance use and metabolic disorders. About MUD Methamphetamine Use Disorder (MUD) is a serious and growing public health concern. Methamphetamine is a highly addictive central nervous system stimulant that can have significant health consequences. According to the 2023 National Survey on Drug Use and Health (NSDUH), approximately 2.6 million people in the United States aged 12 or older reported using methamphetamine in the past year, and 1.6 million people met the criteria for methamphetamine use disorder. Methamphetamine misuse has been associated with a range of adverse health effects, including severe dental disease, cognitive impairment, psychiatric symptoms such as anxiety and psychosis, and damage to the cardiovascular system. Lifetime methamphetamine use has been reported by more than 16 million people in the United States, according to the National Survey on Drug Use and Health. About OUD Opioid Use Disorder (OUD) is a chronic and relapsing medical condition characterized by the problematic use of opioid drugs despite harmful consequences. Opioids are medications commonly prescribed for pain relief that act on the central nervous system and may produce both analgesic effects and feelings of euphoria. OUD can develop through misuse of prescription opioid medications, use of diverted prescription opioids, or use of illicit opioids such as heroin or illegally manufactured fentanyl. According to the 2023 National Survey on Drug Use and Health, approximately 5.7 million people in the United States aged 12 or older were estimated to have an opioid use disorder in the past year. OUD is associated with significant health risks, including overdose, infectious diseases, and increased rates of morbidity and mortality. About Obesity Obesity is a growing global public health concern. According to the World Health Organization, approximately 890 million adults worldwide were living with obesity in 2022, representing about 1 in 8 people globally. Worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled during that time. The World Obesity Federation projects that over 1.5 billion adults could be living with obesity by 2035, and that more than half of the global population, over 4 billion people, may be living with overweight or obesity if current trends continue. The global economic impact of overweight and obesity is projected to exceed $4 trillion annually by 2035, driven by obesity-related conditions such as cardiovascular disease, stroke, cancer, and type 2 diabetes. Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. 25.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke. Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation. Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten. In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen. Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken! Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG. Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.